La bourse est fermée

Merck & Co., Inc. (MRK)

NYSE - NYSE Prix différé. Devise en USD
Ajouter à la liste dynamique
129,48+0,11 (+0,09 %)
À la clôture : 04:00PM EDT
129,45 -0,03 (-0,02 %)
Échanges après Bourse : 07:50PM EDT

Merck & Co., Inc.

126 East Lincoln Avenue
Rahway, NJ 07065
United States
908 740 4000
https://www.merck.com

Secteur(s)Healthcare
Secteur d’activitéDrug Manufacturers - General
Employés à temps plein70 000

Dirigeants clés

NomTitrePayerExercéAnnée de naissance
Mr. Robert M. Davis J.D.Chairman, President & CEO5,57M8,44M1967
Ms. Caroline LitchfieldExecutive VP & CFO3,09MS.O.1969
Mr. Richard R. DeLuca Jr.Executive VP & President of Merck Animal Health2,4M8,03M1963
Mr. Sanat ChattopadhyayExecutive VP & President of Merck Manufacturing Division2,49M12,49M1960
Dr. Dean Y. Li M.D., Ph.D.Executive VP & President of Merck Research Laboratories3,61MS.O.1963
Mr. Dalton E. Smart IIISenior VP of Finance, Principal Accounting Officer & Global ControllerS.O.S.O.1967
Mr. David Michael WilliamsExecutive VP and Chief Information & Digital OfficerS.O.S.O.1969
Mr. Peter DannenbaumVice President of Investor RelationsS.O.S.O.S.O.
Ms. Jennifer L. ZacharyExecutive VP & General Counsel2,73M3,46M1978
Lisa LeCointe-CephasSenior VP and Chief Ethics & Compliance OfficerS.O.S.O.1982
Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Merck & Co., Inc. en date du 1 juin 2024 est 4. Les scores principaux sont Audit : 7; Société : 5; Droits des actionnaires : 3; Compensation : 3.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.